GameChangers: Fezolinetant for Vasomotor Symptoms in Menopause

Menopausal vasomotor symptoms occur in about 80% of women and have a significant impact on quality of life. Hormone replacement therapy works well; however, it is often underused. Join host, Geoff Wall, as he evaluates Fezolinetant, a new medication to treat ‘hot flashes.’

THE GAMECHANGER: HRT is vastly underused in menopausal women. Gabapentin and SNRIs may help with some vasomotor symptoms. Fezolinetant is effective for hot flashes and seems to be well tolerated.

Upon successful completion of this course, learners should be able to:
1. Discuss the pros and cons of hormone replacement therapy in women with vasomotor symptoms.
2. Discuss the role of fezolinetant for treatment of vasomotor symptoms.

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: November 27, 2023
Planned Expiration Date: November 27, 2024

Universal Activity Number (UAN): 0107-0000-23-365-H01-P

Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information

Duration	0h 30m
Topic Designator	Disease State/Drug Therapy
ACPE	Yes
ACPE Topic	01 Drug Therapy
Role	Pharmacist
Media-Type	Podcast
Release Date	11/27/23
CEUs	0.05
Rating	4
ACPE Number	0107-0000-23-365-H01-P